Is PASG or GOVX more profitable?

Passage Bio's return on equity of -150.88% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% GeoVax Labs N/A -709.52% -399.33%

Does the media favor PASG or GOVX?

In the previous week, GeoVax Labs had 5 more articles in the media than Passage Bio. MarketBeat recorded 8 mentions for GeoVax Labs and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.62 beat GeoVax Labs' score of 0.43 indicating that Passage Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeoVax Labs 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GOVX or COCP more profitable?

Cocrystal Pharma's return on equity of -150.61% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% Cocrystal Pharma N/A -150.61% -97.86%

Does the media prefer GOVX or COCP?

In the previous week, GeoVax Labs had 5 more articles in the media than Cocrystal Pharma. MarketBeat recorded 8 mentions for GeoVax Labs and 3 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.96 beat GeoVax Labs' score of 0.43 indicating that Cocrystal Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NAII or GOVX?

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 7,181.55%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Natural Alternatives International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ERNA or GOVX more profitable?

Ernexa Therapeutics' return on equity of -263.74% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -263.74% -151.16% GeoVax Labs N/A -709.52% -399.33%

Does the media favor ERNA or GOVX?

In the previous week, Ernexa Therapeutics had 3 more articles in the media than GeoVax Labs. MarketBeat recorded 11 mentions for Ernexa Therapeutics and 8 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.43 beat Ernexa Therapeutics' score of -0.59 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative GeoVax Labs 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is APLT or GOVX more profitable?

Applied Therapeutics' return on equity of -340.84% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% GeoVax Labs N/A -709.52% -399.33%

GeoVax Labs (GOVX) Competitors

$2.06 -0.34 (-14.17%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.00 (+0.05%)

As of 05/29/2026 07:59 PM Eastern

Compare

GOVX vs. PASG, COCP, NAII, ERNA, and APLT

Should you buy GeoVax Labs stock or one of its competitors? MarketBeat compares GeoVax Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeoVax Labs include Passage Bio (PASG), Cocrystal Pharma (COCP), Natural Alternatives International (NAII), Ernexa Therapeutics (ERNA), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry.

How does GeoVax Labs compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

In the previous week, GeoVax Labs had 5 more articles in the media than Passage Bio. MarketBeat recorded 8 mentions for GeoVax Labs and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.62 beat GeoVax Labs' score of 0.43 indicating that Passage Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeoVax Labs	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 129.64%. GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 7,181.55%. Given GeoVax Labs' higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Passage Bio's return on equity of -150.88% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
GeoVax Labs	N/A	-709.52%	-399.33%

Passage Bio has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.36, meaning that its stock price is 236% more volatile than the broader market.

GeoVax Labs has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
GeoVax Labs	$2.49M	2.87	-$21.47M	-$19.12	N/A

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 0.6% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Passage Bio beats GeoVax Labs on 8 of the 14 factors compared between the two stocks.

How does GeoVax Labs compare to Cocrystal Pharma?

GeoVax Labs (NASDAQ:GOVX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, GeoVax Labs had 5 more articles in the media than Cocrystal Pharma. MarketBeat recorded 8 mentions for GeoVax Labs and 3 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.96 beat GeoVax Labs' score of 0.43 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 0.6% of GeoVax Labs shares are held by company insiders. Comparatively, 28.1% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GeoVax Labs has a beta of 3.36, meaning that its share price is 236% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

GeoVax Labs currently has a consensus target price of $150.00, indicating a potential upside of 7,181.55%. Cocrystal Pharma has a consensus target price of $6.00, indicating a potential upside of 435.71%. Given GeoVax Labs' higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cocrystal Pharma's return on equity of -150.61% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Cocrystal Pharma has lower revenue, but higher earnings than GeoVax Labs. Cocrystal Pharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	2.87	-$21.47M	-$19.12	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

Summary

Cocrystal Pharma beats GeoVax Labs on 9 of the 14 factors compared between the two stocks.

How does GeoVax Labs compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 20.8% of Natural Alternatives International shares are owned by company insiders. Comparatively, 0.6% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, GeoVax Labs had 5 more articles in the media than Natural Alternatives International. MarketBeat recorded 8 mentions for GeoVax Labs and 3 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 0.97 beat GeoVax Labs' score of 0.43 indicating that Natural Alternatives International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeoVax Labs	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Natural Alternatives International has higher revenue and earnings than GeoVax Labs. Natural Alternatives International is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A
GeoVax Labs	$2.49M	2.87	-$21.47M	-$19.12	N/A

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 7,181.55%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Natural Alternatives International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

GeoVax Labs has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Natural Alternatives International's return on equity of -12.21% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
GeoVax Labs	N/A	-709.52%	-399.33%

Natural Alternatives International has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.36, suggesting that its share price is 236% more volatile than the broader market.

Summary

Natural Alternatives International beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

How does GeoVax Labs compare to Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Ernexa Therapeutics has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.36, indicating that its share price is 236% more volatile than the broader market.

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by insiders. Comparatively, 0.6% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ernexa Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 183.82%. GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 7,181.55%. Given GeoVax Labs' higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Ernexa Therapeutics' return on equity of -263.74% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
GeoVax Labs	N/A	-709.52%	-399.33%

Ernexa Therapeutics has higher earnings, but lower revenue than GeoVax Labs. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	21.32	-$14.08M	-$26.20	N/A
GeoVax Labs	$2.49M	2.87	-$21.47M	-$19.12	N/A

In the previous week, Ernexa Therapeutics had 3 more articles in the media than GeoVax Labs. MarketBeat recorded 11 mentions for Ernexa Therapeutics and 8 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.43 beat Ernexa Therapeutics' score of -0.59 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
GeoVax Labs	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ernexa Therapeutics beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

How does GeoVax Labs compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Applied Therapeutics' return on equity of -340.84% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
GeoVax Labs	N/A	-709.52%	-399.33%

In the previous week, GeoVax Labs had 8 more articles in the media than Applied Therapeutics. MarketBeat recorded 8 mentions for GeoVax Labs and 0 mentions for Applied Therapeutics. GeoVax Labs' average media sentiment score of 0.43 beat Applied Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
GeoVax Labs	Neutral

Applied Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 7,181.55%. Given GeoVax Labs' higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Applied Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

GeoVax Labs has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
GeoVax Labs	$2.49M	2.87	-$21.47M	-$19.12	N/A

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 0.6% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.36, suggesting that its stock price is 236% more volatile than the broader market.

Summary

Applied Therapeutics and GeoVax Labs tied by winning 7 of the 14 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOVX vs. The Competition

Export

Metric	GeoVax Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.15M	$3.41B	$6.43B	$12.59B
Dividend Yield	N/A	2.29%	2.69%	5.33%
P/E Ratio	-0.11	18.88	21.61	26.26
Price / Sales	2.87	334.76	561.75	114.93
Price / Cash	N/A	121.88	43.22	56.84
Price / Book	14.71	7.12	10.55	7.30
Net Income	-$21.47M	$24.20M	$3.56B	$337.27M
7 Day Performance	-43.41%	4.11%	2.85%	3.58%
1 Month Performance	88.99%	6.66%	4.58%	5.71%
1 Year Performance	-92.12%	66.32%	37.67%	39.75%

GeoVax Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOVX GeoVax Labs	2.108 of 5 stars	$2.06 -14.2%	$150.00 +7,181.6%	-92.3%	$7.15M	$2.49M	N/A	10	News Coverage Short Interest Increase Gap Down
PASG Passage Bio	2.3844 of 5 stars	$5.12 -1.9%	$13.25 +158.8%	-36.1%	$16.75M	N/A	N/A	130
COCP Cocrystal Pharma	3.1081 of 5 stars	$1.18 -1.7%	$6.00 +408.5%	-28.0%	$16.54M	N/A	N/A	10	Short Interest Decrease
NAII Natural Alternatives International	1.9115 of 5 stars	$2.59 -2.6%	N/A	-24.4%	$16.43M	$129.86M	N/A	290	News Coverage Analyst Forecast Short Interest Decrease
ERNA Ernexa Therapeutics	2.2895 of 5 stars	$12.25 -10.1%	$30.00 +144.9%	-87.7%	$15.90M	$580K	N/A	10	Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOVX) was last updated on 5/30/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeoVax Labs (GOVX) Competitors

GOVX vs. PASG, COCP, NAII, ERNA, and APLT

How does GeoVax Labs compare to Passage Bio?

Summary

How does GeoVax Labs compare to Cocrystal Pharma?

Summary

How does GeoVax Labs compare to Natural Alternatives International?

Summary

How does GeoVax Labs compare to Ernexa Therapeutics?

Summary

How does GeoVax Labs compare to Applied Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeoVax Labs (GOVX) Competitors

GOVX vs. PASG, COCP, NAII, ERNA, and APLT

How does GeoVax Labs compare to Passage Bio?

Does the media favor PASG or GOVX?

Do analysts recommend PASG or GOVX?

Is PASG or GOVX more profitable?

Which has more risk & volatility, PASG or GOVX?

Which has higher valuation and earnings, PASG or GOVX?

Do insiders & institutionals believe in PASG or GOVX?

Summary

How does GeoVax Labs compare to Cocrystal Pharma?

Does the media prefer GOVX or COCP?

Do insiders and institutionals hold more shares of GOVX or COCP?

Which has more volatility and risk, GOVX or COCP?

Do analysts recommend GOVX or COCP?

Is GOVX or COCP more profitable?

Which has higher valuation and earnings, GOVX or COCP?

Summary

How does GeoVax Labs compare to Natural Alternatives International?

Do insiders & institutionals hold more shares of NAII or GOVX?

Does the media refer more to NAII or GOVX?

Which has better valuation and earnings, NAII or GOVX?

Do analysts recommend NAII or GOVX?

Is NAII or GOVX more profitable?

Which has more risk & volatility, NAII or GOVX?

Summary

How does GeoVax Labs compare to Ernexa Therapeutics?

Which has more risk & volatility, ERNA or GOVX?

Do institutionals and insiders believe in ERNA or GOVX?

Do analysts recommend ERNA or GOVX?

Is ERNA or GOVX more profitable?

Which has higher valuation and earnings, ERNA or GOVX?

Does the media favor ERNA or GOVX?

Summary

How does GeoVax Labs compare to Applied Therapeutics?

Is APLT or GOVX more profitable?

Does the media prefer APLT or GOVX?

Do analysts rate APLT or GOVX?

Which has preferable valuation & earnings, APLT or GOVX?

Do institutionals & insiders have more ownership in APLT or GOVX?

Which has more risk & volatility, APLT or GOVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools